Towards a Chlamydia vaccine

Expert Review of Vaccines

Volumn 3, Issue 3, 2004, Pages 237-242

  Igietseme, Joseph ^a,b  

^a MSM   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CHLAMYDIA PROTEIN; CHLAMYDIA VACCINE; UNCLASSIFIED DRUG; VACCINE; BACTERIAL VACCINE;

ACADEMIC ACHIEVEMENT; BACTERIAL GENOME; BACTERIAL STRAIN; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; TRACHOMA; WORLD HEALTH ORGANIZATION; ARTICLE; IMMUNOLOGY; INTERVIEW; RESEARCH;

BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; HUMANS; RESEARCH;

EID: 6044221094     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.3.237     Document Type: Review

References (17)

1. Schachter J. My choice: Chlamydia trachomatis in STDs: early days of the modern era. Sex. Transm. Infect. 76(Suppl. 1) S16 (2000).
2. WHO: Global prevalence and incidence of selected curable sexually transmitted diseases; Overview and estimates. WHO, Geneva, Switzerland (1996).
3. Groseclose SL, Zaidi AA, DeLisle SJ, Levine WC, St. Louis ME. Estimated incidence and prevalence of genital Chlamydia trachomatis infections in the United States, 1996. Sex. Transm. Dis. 26, 339-344 (1999).
4. Johnson RE, Newhall WJ, Papp JR et al. Screening tests to detect Chlamydia and Neisseria gonorrheae infections - 2002. MMWR Morb. Mortal. Wkly Rep. (Recommendations and Reports) 51(RR-15), 1-40 (2002).
5. CDC: Sexually transmitted disease surveillance, 2000, US Department of Health and Human Services, CDC, Atlanta, GA USA (2001).
6. Miller WC, Ford CA, Morris M et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. J. Am. Med. Ass. 291(18), 2229-2236 (2004).
7. Schachter J. NAATs to diagnose Chlamydia trachomatis genital infection: a promise still unfulfilled. Expert Rev. Mol. Diagn. 1(2), 137-144 (2001).
8. Stamm WE. Retrieved Chlamydia trachomatis - the persistent pathogen: Thomas Parran Award Lecture. Sex. Transm. Dis. 28(12), 684-689 (2001).
9. Hammerschlag MR. Chlamydia trachomatis and Chlamydia pneumoniae infections in children and adolescents. Pediatr Rev. 25(2), 43-51 (2004).
10. Byrne GI. Chlamydial treatment failures: a persistent problem? J. Eur. Acad. Dermatol. Venereol. 15(5), 381 (2001).
11. Dean, D, Suchland RJ, Stamm WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J. Infect. Dis. 182, 909-916 (2000).
12. Smith A, Munoz B, Hsieh YH et al. OmpA genotypic evidence for persistent ocular Chlamydia trachomatis infection in Tanzania village women. Ophthalmic Epidemiol. 8(2-3), 127-135 (2001).
13. de la Maza MA, de la Maza LM. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 13(1), 119-127 (1995).
14. Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev. Vaccines 2(1), 129-146 (2003).
15. Igietseme JU, Eko FO, He Q, Bandea C, Black CM. Developing effective delivery systems for Chlamydia vaccines. Curr. Opin. Mol. Therapeutics 6(2), 182-194 (2004).
16. Traggiai E, Chicha L, Mazzucchelli L et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304(5667), 104-107 (2004).
17. Stephens RS, Kalman S, Lammel C et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282(5389), 754-759 (1998).